Combating the dual burden: Therapeutic targeting of common pathways in obesity and type 2 diabetes

Journal: The Lancet Diabetes & Endocrinology December 2014. Conclusion: Combination therapy will probably be necessary to avoid compensatory mechanisms and potentiate initial weight loss while avoiding weight regain. New glucose lowering treatments, especially glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter-2 inhibitors, offer advantages over traditional antidiabetic drugs by promoting weight loss while improving glucose […]

Read More →